The company said Cave is a founder and chairman of its subsidiary, Pharm2Farm Ltd, and is currently involved in an interdisciplinary university research group of 11 PhD’s utilising nanotechnology across a plethora of applications from cancer immunology, and treatments of Alzheimer’s through to food security.
Sartain is currently chief operating officer of Closed Loop Medicine, a firm focused on care pathways and personalised patient regimens.
“We are delighted to welcome both Gareth and Felicity to the Board. They are both highly accomplished in their fields with deep knowledge and experience in nanotechnology. The appointments strengthen and extend the Board’s skill set, and we very much look forward to benefitting over the coming years as their contributions support RMS’s growth trajectory”, RMS executive chairman Antony Legge said in a statement.
Shares in the company were 0.9% lower at 1.6p in early deals on Monday.